ACU-193 is a Monoclonal Antibody owned by Acumen Pharmaceuticals, and is involved in 2 clinical trials, of which 1 is ongoing, and 1 is planned.

ACU-193 acts by binding to soluble amyloid beta oligomers (also called Abeta derived diffusible ligands, ADDLs) with high affinity and selectivity. ADDLs binds to cell surface receptors, leading to synaptic malfunction, long term potentiation (LTP) compromise and memory deficits. Soluble amyloid beta oligomer binding localizes to post-synaptic sites on dendritic spines, accompanied by rapid and persistent up-regulation of arc, an early gene transiently increased at LTP induction. Persistent high levels of arc interfere with LTP. They are able to directly initiate downstream pathological events in Alzheimer's disease. The drug candidate exhibit therapeutic intervention in the treatment of the disease by targeting the oligomers of amyloid beta peptide, thereby improving the synaptic function and memory of Alzheimer patients.

The revenue for ACU-193 is expected to reach a total of $83m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the ACU-193 NPV Report.

ACU-193 was originated by Acumen BioPharma and is currently owned by Acumen Pharmaceuticals.

ACU-193 Overview

ACU-193 is under development for the treatment of Alzheimer's disease and mild cognitive impairment due to AD. It is a fully-humanized, IgG2 murine monoclonal antibody capable of selective binding to soluble abeta oligomers/ADDLs (amyloid precursor protein). It is administered through the intravenous route as infusion. ADDLs are highly ordered aggregates of amyloid-beta 1-42 peptides. It is developed based on ADDL-Select technology.

Acumen Pharmaceuticals Overview

Acumen Pharmaceuticals (Acumen) is a developer of therapeutics and diagnostics for the treatment of Alzheimer’s disease and related neurodegenerative conditions. The company discovers and develops ADDL-Select antibodies that target soluble amyloid-beta oligomers that inhibit nerve function, trigger early memory deficits, initiate nerve cell degeneration and downstream pathological events in Alzheimer’s. Its lead candidate include ACU-193, an anti-ADDL antibody which is in preclinical development stage. Acumen also uses an ultra-high sensitivity assay to measure soluble amyloid-beta oligomer levels in the cerebrospinal fluid in patients to be enrolled in clinical trials.The company owns intellectual property for soluble A-beta oligomers, ADDLs and related therapeutics and diagnostics. Acumen is headquartered in Livermore, California, the US.

The operating loss of the company was US$19.6 million in FY2021, compared to an operating loss of US$7.9 million in FY2020. The net loss of the company was US$100.6 million in FY2021, compared to a net loss of US$7.3 million in FY2020.

Quick View – ACU-193

Report Segments
  • Innovator
Drug Name
  • ACU-193
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.